Ignite Creation Date:
2024-05-06 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 12:52 PM
Study NCT ID:
NCT03649321
Status:
TERMINATED
Last Update Posted:
2023-11-09
First Post:
2018-08-16
Brief Title:
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Sponsor:
University of Texas Southwestern Medical Center
Organization:
University of Texas Southwestern Medical Center
Study Overview
Official Title:
A phase1b2 Clinical Trial of Chemotherapy and the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
Status:
TERMINATED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding was terminated early because research interests were going in a different direction
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determine the overall response rate ORR of bemcentinib plus chemotherapy nab-paclitaxelgemcitabine in patients with metastatic pancreatic adenocarcinoma
Detailed Description:
Bemcentinib inhibits pancreatic cancer proliferation as monotherapy and in combination with gemcitabine through inhibition of the Axl pathway The combination of nab-paclitaxelgemcitabine has encouraging signs of clinical activity in patients with metastatic pancreatic cancer38 We would like to build on this combination in a biomarker driven phase 1b2 clinical trial of bemcentinib in nab-paclitaxelgemcitabine for patients with metastatic pancreatic cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None